We analyzed biotech funding data on our online biopharmIQ platform to identify companies who had early-stage (Angel/Pre-Seed, Seed, Series A round) and late-stage (Series B, C, D, E, and debt financing) biotech with $1M+ funding events in November 2024 (FIG.1). Our team uses automated and manual systems daily to identify biotech funding events.
FIG. 1. Number of biotech companies with $1M+ early & late-stage funding events worldwide in November 2024
With respect to the funding types, Seed, Series A, and Debt Financing share the top spot, with 9 reported funding events captured each, closely followed by Series B with 8 funding events. Series C follows with 3 funding events, while Series D and Series E round out the observed late-stage funding each recording 2 events (FIG. 2).
FIG. 2. Early & Late-Stage Biotech Funding Types with $1M+ funding events in November 2024
Early-Stage Funded Biotech Companies
With respect to countries with the most companies with $1M+ early-stage funding events in November 2024 (FIG. 3), not surprisingly the U.S. (8 companies) was at the top of the list for these types of funding events that were captured by our systems. However, there were some surprises in the data. We were surprised to see India and China had almost the same number (2 companies) of funding events. Meanwhile, Switzerland, Japan, Israel, France, Belgium, and Australia followed, each with 1 company receiving early-stage investments in November 2024.
FIG. 3. Number of biotech companies with $1M+ early-stage funding events worldwide in November 2024
In the U.S. (FIG. 4), not surprisingly when we analyzed the data from our powerful online biopharmIQ platform, California led with 4 companies, respectively, that had $1M+ early-stage funding events in November 2024. Perhaps more surprising is that Texas (2 companies) is next on the list. It is worth noting that Massachusetts had no $1M+ early-stage funding event in November 2024.
FIG. 4. Number of biotech companies with $1M+ early-stage funding events in the U.S. in November 2024.
Finally, in terms of company types that had $1M+ early-stage funding events (FIG. 5), therapeutic companies (11 companies) had the most events. Funding events for vendor company types (2 companies) and diagnostics company types (2 companies) ranked second for these types of funding events that were captured by our systems.
FIG. 5. Number of company types with $1M+ early-stage funding events in November 2024.
Late-Stage Funded Biotech Companies
For countries with the most companies with $1M+ late-stage funding events* in November 2024 (FIG. 6), not surprisingly the United States (14 companies) led the list for these types of funding events that were captured by our systems. Canada (2 companies) ranked second with $1M+ late-stage funding events in November 2024.
FIG. 6. Number of biotech companies with $1M+ late-stage funding events worldwide in November 2024
In the U.S., not surprisingly, California led the list (5 companies) with $1M+ late-stage funding events in November 2024 (FIG. 7). In contrast with the early-stage funding above, Massachusetts (3 companies) ranked second among the late-stage funded companies. Meanwhile, Virginia, Texas, New Jersey, and Kansas each had 1 $1M+ late-stage funding event respectively.
FIG. 7. Number of biotech companies with $1M+ late-stage funding events in the U.S. in November 2024.
Finally, with respect to the company types that received $1M+ late-stage funding (FIG. 8), therapeutic companies, at 15 total, had the most. Meanwhile, medical device companies secured 5 funding events, and vendor companies accounted for 3 events. Diagnostics companies, with 1 recorded event, completed the late-stage funding landscape as captured by our systems.
FIG. 8. Number of company types with $1M+ late-stage funding events in November 2024.
We look forward to analyzing the December data so that we can provide our 2024 annual report.
You can check out recent funding data on our online biopharmIQ platform. Want to see our online platform in action? Watch a short demo video of our platform. Get instant access to all our data/modules: Check out our affordable pricing plans, which come with a satisfaction guarantee.
Have questions or want to schedule an online demo?
Contact marketing@biopharmIQ.com.
***
Article History:
12/30/24 MV/RF/JD/DG
Not legal, investing, or tax advice.
Comments